Publication | Open Access
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
29
Citations
15
References
2021
Year
Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.
| Year | Citations | |
|---|---|---|
Page 1
Page 1